CCK-BR Antibody (E-3): sc-166690

CCK-BR Antibody (E-3) is a mouse monoclonal IgG1 kappa light chain antibody that detects CCK-BR protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA). CCK-BR (E-3) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. CCK-BR plays a crucial role in the gastrointestinal system by mediating the effects of cholecystokinin (CCK) and gastrin, which are vital for digestive processes. CCK-BR is located on the surface of pancreatic acinar cells and enteroendocrine cells, where CCK-BR facilitates the secretion of digestive enzymes and bile, thereby enhancing nutrient absorption. This localization underscores CCK-BR′s role in coordinating digestive functions and maintaining homeostasis within the gastrointestinal tract. The interaction of CCK-BR with CCK-BR′s ligands influences digestive enzyme release and impacts satiety signaling in the central nervous system, highlighting CCK-BR′s potential as a therapeutic target for gastrointestinal and metabolic disorders.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CCK-BR Antibody (E-3) References:

1. Signaling pathways mediating gastrin's growth-promoting effects.  |  Yassin, RR. 1999. Peptides. 20: 885-98. PMID: 10477091
2. Therapeutic and chemical developments of cholecystokinin receptor ligands.  |  de Tullio, P., et al. 2000. Expert Opin Investig Drugs. 9: 129-46. PMID: 11060666
3. Involvement of cholecystokinin within craving for cocaine: role of cholecystokinin receptor ligands.  |  Crespi, F., et al. 2000. Expert Opin Investig Drugs. 9: 2249-58. PMID: 11060804
4. Molecular mechanisms for the antiapoptotic action of gastrin.  |  Todisco, A., et al. 2001. Am J Physiol Gastrointest Liver Physiol. 280: G298-307. PMID: 11208554
5. Loxiglumide, a CCK-A receptor antagonist, stimulates calorie intake and hunger feelings in humans.  |  Beglinger, C., et al. 2001. Am J Physiol Regul Integr Comp Physiol. 280: R1149-54. PMID: 11247838
6. Cholecystokinin, cholecystokinin-A receptor and cholecystokinin-B receptor gene polymorphisms in Parkinson's disease.  |  Wang, J., et al. 2003. Pharmacogenetics. 13: 365-9. PMID: 12777967
7. Cholecystokinin-B receptor gene expression in cerebellum, pre-frontal cortex and cingulate gyrus and its association with suicide.  |  Sherrin, T., et al. 2004. Neurosci Lett. 357: 107-10. PMID: 15036586
8. The gastrin/cholecystokinin-B receptor on prostate cells--a novel target for bifunctional prostate cancer imaging.  |  Sturzu, A., et al. 2014. Eur J Pharm Sci. 52: 69-76. PMID: 24211650
9. A Cholecystokinin B Receptor-Specific DNA Aptamer for Targeting Pancreatic Ductal Adenocarcinoma.  |  Clawson, GA., et al. 2017. Nucleic Acid Ther. 27: 23-35. PMID: 27754762
10. Intestinal Gastrin/CCKBR (Cholecystokinin B Receptor) Ameliorates Salt-Sensitive Hypertension by Inhibiting Intestinal Na+/H+ Exchanger 3 Activity Through a PKC (Protein Kinase C)-Mediated NHERF1 and NHERF2 Pathway.  |  Jiang, X., et al. 2022. Hypertension. 79: 1668-1679. PMID: 35674015
11. Molecular cloning and sequencing of the murine gastrin gene.  |  Koh, TJ. and Wang, TC. 1995. Biochem Biophys Res Commun. 216: 34-41. PMID: 7488110
12. The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients.  |  van Megen, HJ., et al. 1997. Psychopharmacology (Berl). 129: 243-8. PMID: 9084062

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-CCK-BR Antibody (E-3) has 9 citations in a variety of scientific publications.

Primary antibodies like Anti-CCK-BR Antibody (E-3) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

CCK-BR Antibody (E-3) Specifications

Alternate Product Name: CCK-BR

Product Clone Name: E-3

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 1-85

Epitope Target: CCK-BR

Epitope Species: human

Product Reactivity/Detection: CCK-BR

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 9 citations in various scientific publications

Available Conjugates/Forms for CCK-BR Antibody (E-3): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin